|
Eckert & Ziegler SE / Key word(s): Preliminary Results Eckert & Ziegler Announces Preliminary Figures for 2024: Significant Increase in Sales and Adjusted EBIT 27-Jan-2025 / 18:55 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group. The issuer is solely responsible for the content of this announcement. Financial Year 2024 (preliminary):
Berlin, 27 January 2025. According to preliminary, unaudited figures, Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) generated sales of around EUR 295 million and an adjusted EBIT of around EUR 66 million in the 2024 financial year. Sales increased by 20% compared to the previous year. Adjusted EBIT is even 41% higher than in the previous year and thus above the raised forecast for FY 2024 issued on 22 November 2024. Net profit (from continued and discontinued operations), which is only reported here for comparison purposes, rose to around EUR 33 million (previous year: EUR 26.3 million). The guidance for the 2025 financial year will be published on 27 March 2025 together with the complete, audited annual financial statements for 2024. Contact: End of Inside Information 27-Jan-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
FDA advisory panel signals lack of confidence in data on Amgen’s cancer drug
The clearance of a first-of-its-kind cancer treatment made by Amgen is on shakier ground following a Food and Drug Administration advisory committee meeting Thursday. Regulatory
October 5, 2023